Acute optic neuritis - Pipeline Insight, 2024

This “Acute optic neuritis - Pipeline Insight, 2024,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Acute optic neuritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acute optic neuritis Understanding

Acute optic neuritis: Overview

Optic neuritis is an inflammatory disease of the optic nerve and is frequently the presenting sign of multiple sclerosis. These patients commonly experience pain on eye movement and then suddenly have a major loss in visual acuity, usually in one eye. The blindness often resolves in 6-8 weeks. Six months after the episode of blindness, more than half of the patients have some visual changes, including deficits in color vision, contrast sensitivity, and light brightness. The current treatment is steroids, which reduce the period of visual acuity loss but have little or no effect on the preventing damage to contrast vision.

Acute optic neuritis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute optic neuritis pipeline landscape is provided which includes the disease overview and Acute optic neuritis treatment guidelines. The assessment part of the report embraces, in depth Acute optic neuritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute optic neuritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Acute optic neuritis R&D. The therapies under development are focused on novel approaches to treat/improve Acute optic neuritis.

Acute optic neuritis Emerging Drugs Chapters

This segment of the Acute optic neuritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute optic neuritis Emerging Drugs

BN201: BionureBN201 is a new chemical and first-in-class compound that demonstrated neuroprotective activity i.e. stimulation for axonal protection, remyelination and promotion of neuronal survival in preclinical models, making it an ideal candidate for facilitating neuroprotection from degenerative, ischemic, toxic and inflammatory diseases of the nervous system.

ST266: NoveomeST266 is a first-of-its-kind, multi-targeted, non-cellular platform biologic with the potential to improve patients’ outcomes across a range of challenging diseases and conditions in ophthalmology, neurology, dermatology - and more. ST266 is produced by collecting the secretome from a novel population of cells generated by a proprietary method of culturing amnion-derived epithelial cells from donated full-term placentas, normally discarded after birth. The drug is in phase 1 of clinical trials for the treatment of optic neuritis.

Acute optic neuritis: Therapeutic Assessment

This segment of the report provides insights about the different Acute optic neuritis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute optic neuritis

There are approx. 2+ key companies which are developing the therapies for Acute optic neuritis. The companies which have their Acute optic neuritis drug candidates in the most advanced stage, i.e. phase II include, Bionure

Phases

This report covers around 2+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Acute optic neuritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute optic neuritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute optic neuritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute optic neuritis drugs.

Acute optic neuritis Report Insights

• Acute optic neuritis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute optic neuritis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute optic neuritis drugs?
• How many Acute optic neuritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute optic neuritis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute optic neuritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute optic neuritis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bionure
• Noveome
• Lipocure

Key Products

• BN201
• ST-266
• LC200